OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
MMIX57

Multi Medika Internasional Tbk PT

Medical Equipment, Supplies & DistributionVerified

The company’s capital structure is characterized by a lack of detailed liquidity metrics, as no balance-sheet inputs are available, and no going-concern language is present in the source documents. This limits the ability to assess short-term liquidity risk or debt obligations. The absence of a clear liquidity profile also prevents a full evaluation of the company’s ability to meet immediate financial obligations. Profitability and return metrics are not available in the provided data, which limits the ability to compare the company’s performance against industry_config preferred metrics or cohort medians. Without access to key profitability indicators such as EBITDA margins, net profit margins, or ROIC, it is not possible to assess the company’s efficiency or return generation relative to its peers. The company’s revenue is concentrated in the wholesale trade of medical and health-related products, including face masks, hazmat suits, and diagnostic kits. It also distributes consumer goods under the INDOMARET and Alfamart brands. However, the data does not provide a breakdown of revenue by segment or geography, making it difficult to assess exposure to specific markets or product lines. Growth trajectory is not quantifiable due to the absence of historical revenue data or forward-looking guidance. The outlook for the current and next fiscal years is not provided, and no numeric deltas are available to assess potential revenue or margin expansion. The company’s exposure to public health trends and consumer demand for personal protective equipment may influence its performance, but this is speculative without concrete data. Risk factors include the inability to assess liquidity risk due to missing balance-sheet data and the lack of going-concern language in source documents. The dilution potential is currently low, as the number of basic and diluted shares outstanding is identical, indicating no recent or expected share issuance. However, the absence of a liquidity profile and the reliance on wholesale trade expose the company to supply chain and demand volatility. Recent events and filings are not detailed in the provided data, and no transcripts or disclosures are available to assess management commentary or strategic direction. The company’s exposure to public health events, such as the ongoing demand for face masks and health care products, may influence its operations, but this is not quantified in the available information.

30-day price · MMIX+174.00 (+83.7%)
Low$206.00High$410.00Close$382.00As of13 May, 00:00 UTC
Profile
CompanyMulti Medika Internasional Tbk PT
TickerMMIX.JK
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
AI analysis

Business. PT Multi Medika Internasional Tbk operates in the healthcare services and equipment sector, primarily engaged in the wholesale trading of laboratory equipment, pharmaceutical equipment, medical devices, and related products, including face masks and health care supplies under its MIU and INDOMARET brands.

Classification. The company is classified under the industry "Medical Equipment, Supplies & Distribution" within the Healthcare Services & Equipment business sector, with a confidence level of 0.92.

The company’s capital structure is characterized by a lack of detailed liquidity metrics, as no balance-sheet inputs are available, and no going-concern language is present in the source documents. This limits the ability to assess short-term liquidity risk or debt obligations. The absence of a clear liquidity profile also prevents a full evaluation of the company’s ability to meet immediate financial obligations. Profitability and return metrics are not available in the provided data, which limits the ability to compare the company’s performance against industry_config preferred metrics or cohort medians. Without access to key profitability indicators such as EBITDA margins, net profit margins, or ROIC, it is not possible to assess the company’s efficiency or return generation relative to its peers. The company’s revenue is concentrated in the wholesale trade of medical and health-related products, including face masks, hazmat suits, and diagnostic kits. It also distributes consumer goods under the INDOMARET and Alfamart brands. However, the data does not provide a breakdown of revenue by segment or geography, making it difficult to assess exposure to specific markets or product lines. Growth trajectory is not quantifiable due to the absence of historical revenue data or forward-looking guidance. The outlook for the current and next fiscal years is not provided, and no numeric deltas are available to assess potential revenue or margin expansion. The company’s exposure to public health trends and consumer demand for personal protective equipment may influence its performance, but this is speculative without concrete data. Risk factors include the inability to assess liquidity risk due to missing balance-sheet data and the lack of going-concern language in source documents. The dilution potential is currently low, as the number of basic and diluted shares outstanding is identical, indicating no recent or expected share issuance. However, the absence of a liquidity profile and the reliance on wholesale trade expose the company to supply chain and demand volatility. Recent events and filings are not detailed in the provided data, and no transcripts or disclosures are available to assess management commentary or strategic direction. The company’s exposure to public health events, such as the ongoing demand for face masks and health care products, may influence its operations, but this is not quantified in the available information.
Key takeaways
  • The company operates in the healthcare services and equipment sector, focusing on wholesale trade of medical and consumer health products.
  • Liquidity risk cannot be assessed due to missing balance-sheet data and no going-concern language in source documents.
  • Profitability and return metrics are not available, limiting the ability to benchmark against industry peers.
  • Revenue concentration is likely in medical and consumer health products, but no segment or geographic breakdown is provided.
  • Growth trajectory and outlook are speculative due to the absence of historical revenue data or forward guidance.
  • Dilution risk is currently low, but liquidity and operational risks remain unquantified.
  • --
  • # RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyIDR
Revenue
Gross profit
Operating income
Net income
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets
Total liabilities
Total equity
Cash & equivalents
Long-term debt
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book
Net cash
Current ratio
Debt/Equity
ROA
ROE
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskUnknown
  • Liquidity risk could not be assessed (no balance-sheet inputs and no going-concern language in source documents).
Industry benchmarks
Activity: Healthcare Services & Equipment · cohort 5 companies
MetricMMIXActivity
Op margin13.3% medp25 5.9% · p75 13.5%
Net margin8.6% medp25 2.7% · p75 12.7%
Gross margin64.0% medp25 60.1% · p75 65.6%
R&D / revenue6.9% medp25 6.7% · p75 7.1%
CapEx / revenue3.0% medp25 2.7% · p75 4.5%
Debt / equity69.3% medp25 63.4% · p75 74.5%
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 06:34 UTC#d80cce37
Market quoteclose IDR 302.00 · shares 4.80B diluted
no public URL
2026-05-04 02:48 UTC#35f846e0
Source: analysis-pipeline (hybrid)Generated: 2026-05-10 06:35 UTCJob: fcab9b12